Drugs / 5 flucytosine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03294486 | Oct 2017 → May 2019 | brain cancer, glioblastoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00847678 | Aug 2006 → Nov 2007 | Cryptococcal meningitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04657315 Background | Jun 2020 → Dec 2022 | gliosarcoma | CHA University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5 flucytosine | “Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day” NCT04657315 ↗ |
| Route | Oral | “5-FC administered orally as 500 mg tablets taken 4 times per day (qid)” NCT03294486 ↗ |